valsartan has been researched along with Hyperkalemia in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 7 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, E; Ishigami, J; Miller, ER; Moran, AE; Pfister, M; Qin, L; Zhang, N | 1 |
| Bedhomme, S; Bouchant, S; Boussageon, R; Bœuf-Gibot, S; Charuel, E; Menini, T; Pereira, B; Piñol-Domenech, N; Vaillant-Roussel, H | 1 |
| Lang, H; Melk, A; Schmidt, BMW; Vollmer Barbosa, C | 1 |
| Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM | 1 |
| Gao, M; Gu, L; Hou, Y; Ma, K; Wang, X; Zhang, F; Zhang, Y; Zheng, S | 1 |
| Ashraf, T; Balouch, IJ; Bashir, S; Bhatti, UH; Karim, M; Khan, MN; Moazzam, A; Naseeb, K; Rauf, R; Soomro, NA | 1 |
| Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S | 1 |
| Adie, S; Bitar, A; Dorsch, M; Hanigan, S; Koelling, T; Pogue, K | 1 |
| Jacob, MS; Sabe, MA; Taylor, DO | 1 |
| Brown, NJ; Hubers, SA | 1 |
| Anand, I; Andreka, P; Charney, A; Chen, F; Cosmi, F; Fischer, S; Galve, E; Gelev, V; Gogia, H; Gómez-Doblas, JJ; Majercak, I; Martinez-Selles, M; McIntyre, HF; McMurray, JJ; Nociar, J; Radomska, M; Reimund, B; Reyes, A; Sarkar, A; Senni, M; Shehova-Yankova, N; Sokolova, B; Volterrani, M; Wachter, R; Yilmaz, MB; Zilahi, Z | 1 |
| Ezekowitz, JA | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR | 1 |
| Huynh, K | 1 |
| Cheng, J | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Oparil, S; Patel, S; Satlin, A; Yarows, SA; Zhang, J | 1 |
| Chrysant, SG; Dattani, D; Hoppe, UC; Hsu, H; Murray, AV; Patel, S; Zhang, J | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
5 review(s) available for valsartan and Hyperkalemia
| Article | Year |
|---|---|
Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperkalemia; Hypertension; Hypokalemia; Tetrazoles; Valsartan | 2022 |
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypotension; Mortality; Renal Insufficiency; Risk Assessment; Stroke Volume; Valsartan | 2021 |
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Humans; Hyperkalemia; Neprilysin; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Valsartan | 2022 |
Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Pharmacovigilance; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Topics: Abnormalities, Drug-Induced; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bradykinin; Contraindications; Drug Combinations; Drug Costs; Drug Synergism; Enalapril; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Hypertension; Kidney; Multicenter Studies as Topic; Natriuretic Peptides; Neprilysin; Pregnancy; Prodrugs; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Thiazepines; Valsartan | 2016 |
5 trial(s) available for valsartan and Hyperkalemia
| Article | Year |
|---|---|
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperkalemia; Hypotension; Pyrimidines; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2022 |
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2023 |
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Cough; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Valsartan | 2015 |
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
9 other study(ies) available for valsartan and Hyperkalemia
| Article | Year |
|---|---|
Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Hyperkalemia; Kidney; Potassium; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Retrospective Studies; Tetrazoles; Valsartan | 2019 |
Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan | 2017 |
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Neprilysin; Tetrazoles; Valsartan | 2017 |
Sacubitril/Valsartan (Entresto) for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Neprilysin; Renal Insufficiency; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Dual inhibition of the renin system by aliskiren and valsartan.
Topics: Amides; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Hyperkalemia; Hypertension; Renin; Tetrazoles; Valine; Valsartan | 2007 |
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Fumarates; Humans; Hydrochlorothiazide; Hyperkalemia; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |